Big opportunities for small molecules in immuno-oncology
JL Adams, J Smothers, R Srinivasan… - Nature reviews Drug …, 2015 - nature.com
The regulatory approval of ipilimumab (Yervoy) in 2011 ushered in a new era of cancer
immunotherapies with durable clinical effects. Most of these breakthrough medicines are …
immunotherapies with durable clinical effects. Most of these breakthrough medicines are …
Research trends in pharmacological modulation of tumor‐associated macrophages
N Wang, S Wang, X Wang, Y Zheng… - Clinical and …, 2021 - Wiley Online Library
As one of the most abundant immune cell populations in the tumor microenvironment (TME),
tumor‐associated macrophages (TAMs) play important roles in multiple solid malignancies …
tumor‐associated macrophages (TAMs) play important roles in multiple solid malignancies …
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial
A Patnaik, TA Yap, HC Chung, MJ de Miguel… - Clinical Cancer …, 2021 - AACR
Abstract Purpose: This phase Ia/Ib PACT study evaluated the safety, pharmacokinetics,
pharmacodynamics, and antitumor activity of a new programmed cell death ligand 1 (PD-L1) …
pharmacodynamics, and antitumor activity of a new programmed cell death ligand 1 (PD-L1) …
Tailoring therapies to counter the divergent immune landscapes of breast cancer
Breast cancer remains a significant clinical concern affecting millions of women worldwide.
Immunotherapy is a rapidly growing drug class that has revolutionized cancer treatment but …
Immunotherapy is a rapidly growing drug class that has revolutionized cancer treatment but …
MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages
ML Babicky, MM Harper, J Chakedis, A Cazes… - Oncogene, 2019 - nature.com
Abstract The MST1R (RON) kinase is overexpressed in> 80% of human pancreatic cancers,
but its role in pancreatic carcinogenesis is unknown. In this study, we examined the …
but its role in pancreatic carcinogenesis is unknown. In this study, we examined the …
Myeloid cells as targets for therapy in solid tumors
It is well established that cancer development ensues based on reciprocal interactions
between genomically altered neoplastic cells and diverse populations of recruited “host” …
between genomically altered neoplastic cells and diverse populations of recruited “host” …
[HTML][HTML] Small-molecule agents for cancer immunotherapy
F Wang, K Fu, Y Wang, C Pan, X Wang, Z Liu… - … Pharmaceutica Sinica B, 2023 - Elsevier
Cancer immunotherapy, exemplified by the remarkable clinical benefits of the immune
checkpoint blockade and chimeric antigen receptor T-cell therapy, is revolutionizing cancer …
checkpoint blockade and chimeric antigen receptor T-cell therapy, is revolutionizing cancer …
Preclinical efficacy of Ron kinase inhibitors alone and in combination with PI3K inhibitors for treatment of sfRon-expressing breast cancer patient-derived xenografts
M Bieniasz, P Radhakrishnan, N Faham… - Clinical Cancer …, 2015 - AACR
Purpose: Recent studies have demonstrated that short-form Ron (sfRon) kinase drives
breast tumor progression and metastasis through robust activation of the PI3K pathway. We …
breast tumor progression and metastasis through robust activation of the PI3K pathway. We …
OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase
C Hao, Y Cui, S Chang, J Huang, E Birkin, M Hu… - Scientific Reports, 2019 - nature.com
Osteopontin (OPN) is identified as a diagnostic and prognostic biomarker of tumor
progression and metastasis. In non-small-cell lung cancer (NSCLC), the functions of OPN …
progression and metastasis. In non-small-cell lung cancer (NSCLC), the functions of OPN …
Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets
FM Franco, DE Jones, PKW Harris, Z Han… - Bioorganic & Medicinal …, 2015 - Elsevier
Hepatocyte growth factor activator (HGFA), matriptase and hepsin are all S1 trypsin-like
serine endopeptidases. HGFA is a plasma protease while hepsin and matriptase are type II …
serine endopeptidases. HGFA is a plasma protease while hepsin and matriptase are type II …